Moderna Beats Q2 Estimates as FDA mRNA Flu Vaccine Decision Nears

Moderna Surpasses Q2 2026 Revenue Forecasts Ahead of Critical FDA mRNA Flu Vaccine Ruling 

BENGALURU, India — July 31, 2026 — Moderna, Inc. reported second-quarter 2026 revenue of USD 145 million, surpassing Wall Street's consensus estimate of USD 103 million, as the biotech company awaits a pivotal U.S. Food and Drug Administration decision on its mRNA-based seasonal influenza vaccine by August 5. The development carries significant implications for the global biopharmaceuticals industry, which is estimated at USD 520 billion in 2026 and is forecast to reach USD 972.2 billion by 2035, expanding at a 7.2% compound annual growth rate. 

The quarterly revenue beat was supported by vaccine partnership payments from the governments of the United Kingdom, Canada, and Australia, alongside continued international sales of Moderna's COVID-19 shot. The company's second-quarter net loss of USD 1.97 per share also came in narrower than analyst expectations of USD 2.08 per share, reflecting ongoing cost discipline across the organization. 

Moderna's research and development expenses declined 7% year-over-year to USD 651 million in the quarter, driven by the wind-down of several late-stage programs. The company revised its full-year R&D expense outlook downward to approximately USD 2.9 billion, compared with its prior forecast of USD 3.0 billion, while reiterating its expectation of up to 10% revenue growth for the full year 2026. 

The FDA's anticipated ruling on Moderna's mRNA flu vaccine — which, if approved, would represent the first seasonal influenza shot in the United States developed using mRNA technology — remains the most closely watched near-term catalyst for the company. A panel of external FDA advisers backed the vaccine's approval in June 2026, following an initial regulatory setback under former Commissioner Marty Makary before a revised filing was accepted. 

Key Highlights: 

• Revenue Beat: Q2 2026 total revenue of USD 145 million exceeded analyst estimates of USD 103 million, supported by international COVID-19 vaccine sales and government partnership payments. 

• Narrower Loss: Q2 net loss of USD 1.97 per share came in below the expected USD 2.08 per share, reflecting cost reduction progress. 

• FDA mRNA Flu Vaccine Decision: The U.S. FDA is expected to rule on Moderna's first-of-its-kind mRNA seasonal flu vaccine by August 5, 2026, a milestone that could expand the mRNA platform beyond COVID-19. 

• Pipeline Advancement: Moderna is advancing intismeran autogene, an individualized mRNA cancer therapy co-developed with Merck & Co., Inc., across multiple oncology indications, with late-stage melanoma data expected later in 2026. 

Analyst Insight: 

According to analysts at Next Move Strategy Consulting, Moderna's Q2 performance underscores the growing commercial resilience of the mRNA platform as the company diversifies its revenue base beyond COVID-19 through government partnerships and pipeline expansion. NMSC analysts note that a favorable FDA ruling on the mRNA flu vaccine would represent a structural inflection point for the broader biopharmaceuticals market, validating the RNA therapeutics modality — currently the fastest-growing biologic therapeutic segment at a 13.9% CAGR from 2026 to 2035 — as a commercially viable platform across multiple infectious disease and oncology indications. The firm further observes that Moderna's disciplined R&D cost management, combined with its advancing oncology pipeline, positions the company to capture incremental market share as the global biopharmaceuticals sector scales toward its projected USD 972.2 billion valuation by 2035. 

Industry Outlook: 

The pending FDA decision on Moderna's mRNA flu vaccine arrives at a pivotal moment for the biopharmaceuticals industry. If approved, it would mark the first regulatory validation of mRNA technology for a non-COVID-19 infectious disease indication in the United States, potentially accelerating adoption of the platform across respiratory, oncology, and rare disease pipelines. The biopharmaceuticals market's RNA therapeutics segment is already projected to expand at a 13.9% CAGR through 2035, the fastest rate among all biologic therapeutic categories, reflecting sustained investor and manufacturer confidence in the modality's long-term commercial potential. 

Moderna's concurrent advancement of its mRNA cancer therapy with Merck, with late-stage melanoma data anticipated in the second half of 2026, adds a further dimension to the company's pipeline narrative. Barclays analysts have estimated the therapy could generate approximately USD 3 billion in adjuvant melanoma revenues by 2035. Meanwhile, the norovirus vaccine candidate's interim setback — attributed to a lower-than-anticipated infection rate in the ongoing trial — is expected to extend the study timeline by one additional winter season, representing a delay rather than a program termination. 

Collectively, these developments reflect the broader industry dynamic in which mRNA platform companies are navigating a transition from pandemic-era revenue concentration toward diversified, multi-indication commercial portfolios — a shift that will define competitive positioning within the global biopharmaceuticals market through the remainder of the decade. 

Source: Reuters

For More Information – Download FREE Sample on Biopharmaceuticals Market Report

Prepared By: Sanyukta Deb